<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="84017">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01960049</url>
  </required_header>
  <id_info>
    <org_study_id>12-0493-A</org_study_id>
    <nct_id>NCT01960049</nct_id>
  </id_info>
  <brief_title>Novel Technique of Analgesia Following Open Liver Resection</brief_title>
  <official_title>Multicentre Evaluation of a Novel Technique of Analgesia Following Open Liver Resection: Medial Open Transversus Abdominis Plane (MOTAP) Catheters</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Health Network, Toronto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Health Network, Toronto</source>
  <oversight_info>
    <authority>Canada: Ethics Review Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Abdominal wall incisions used for liver surgeries are associated with significant
      postoperative pain and disability. Epidural analgesia is often contraindicated in these
      patients due to common bleeding problems. Furthermore, drugs such as acetaminophen and
      opioids are often inadequate and can lead to detrimental side-effects. Abdominal wall (AW)
      catheters can be placed during surgical closure along the incision line and can be used to
      administer local anesthetics for postoperative pain. The study is a multi-centre,
      double-blind, randomized controlled trial involving 120 patients undergoing elective liver
      surgery. Patients will be randomly assigned to AW catheter group treated with drug or
      control treated with saline. Treatment group will receive AW catheters with ropivacaine plus
      standard patient controlled analgesia (PCA). Control group will obtain AW with normal saline
      and no local anesthetics and PCA. Patients are followed for 6 months post-operatively for
      pain scores, side-effects, chronic pain and complications.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Anticipated">September 2015</completion_date>
  <primary_completion_date type="Anticipated">July 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Opioid consumption</measure>
    <time_frame>72 hours and  5 days (average HLOS)</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Pain</measure>
    <time_frame>3 tiiems daily for 48 hours then daily until discharge ( 5 day average)</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Postoperative Pain</condition>
  <condition>Liver Resection</condition>
  <arm_group>
    <arm_group_label>MOTAP Catheter with Saline and IV PCA</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Control group will have saline 20cc of 0.9% normal saline injected into the catheters and then run at 5ml/hr for 72 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MOTAP catheter with ropivocaine and  IV PCA</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>20cc of 0.2% ropivacaine will be injected in two equal divided doses through the two catheters then run at 5ml/hr for 72 hours</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>ropivacaine + iv PCA</intervention_name>
    <arm_group_label>MOTAP catheter with ropivocaine and  IV PCA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>saline and IV PCA</intervention_name>
    <arm_group_label>MOTAP Catheter with Saline and IV PCA</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  &gt;18 years age

          -  Undergoing liver resection using a subcostal incision

        Exclusion Criteria:

          -  Patients unable to comprehend instructions, consent, or co-operate with pain
             assessment (including psychiatric disorders, pre-operative sedation, coma)

          -  Allergy to any study medications

          -  Patient not able to be extubated postoperatively for any clinical reason

          -  Laparoscopic surgery

          -  Co-existing epidural or intrathecal analgesia

          -  Chronic pain disorders or on long-term opioid use

          -  History of substance or alcohol abuse

          -  Transplant donor liver resections

          -  Patients with liver cirrhosis
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hance Clarke, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Toronto General Hospital, University Health Network</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hance Clarke, MD</last_name>
    <phone>416-340-4800</phone>
    <phone_ext>6649</phone_ext>
    <email>hance.clarke@uhn.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jo Carroll</last_name>
    <phone>416-340-4800</phone>
    <phone_ext>3243</phone_ext>
    <email>jo.carroll@uhn.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sunnybrook Health Science Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul Karanicolas, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Jenny Lam-McCulloch</last_name>
      <email>Jenny.Lam-McCulloch@sunnybrook.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Paul McHardy, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jason Sawyer</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Calvin Law, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Natalie Coburn, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sherif Hanna, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alex Kiss, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ramy Behman, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jenny Lam-McCulloch</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stuart McCLuskey, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Coimbatore Srinivas, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Toronto General Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2C4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hance Clarke, MD</last_name>
      <phone>416-340-4800</phone>
      <phone_ext>6649</phone_ext>
      <email>hance.clarke@uhn.ca</email>
    </contact>
    <contact_backup>
      <last_name>Jo Carroll</last_name>
      <phone>416-340-4800</phone>
      <phone_ext>3243</phone_ext>
      <email>jo.carroll@uhn.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Alice Wei, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stuart McCluskey, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sean Cleary, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Salima Ladik, RN</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Joel Katz, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Toronto General Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2C4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hance Clarke, MD</last_name>
      <phone>416-340-4800</phone>
      <phone_ext>6649</phone_ext>
      <email>hance.clarke@uhn.ca</email>
    </contact>
    <contact_backup>
      <last_name>Jo Carroll</last_name>
      <phone>416-340-4800</phone>
      <phone_ext>3243</phone_ext>
      <email>jo.carroll@uhn.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Hance Clarke, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <lastchanged_date>March 28, 2014</lastchanged_date>
  <firstreceived_date>September 23, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Postoperative pain</keyword>
  <keyword>Liver resection</keyword>
  <keyword>Medial Open Transversus Abdominis Plane catheter</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ropivacaine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
